2f:I[703058,["/_next/static/immutable/chunks/3bhq_5eh1d760.js","/_next/static/immutable/chunks/2iy5wruuedsh6.js","/_next/static/immutable/chunks/2pfsjpn6k6zlg.js","/_next/static/immutable/chunks/26c7v3_3uwnwu.js","/_next/static/immutable/chunks/00yc7rcvua6a7.js","/_next/static/immutable/chunks/37ktb71aq3480.js","/_next/static/immutable/chunks/2d50b-7eu4558.js","/_next/static/immutable/chunks/06_yt270h41rg.js","/_next/static/immutable/chunks/2d6noqpp6ehas.js","/_next/static/immutable/chunks/1sx186c93bpzg.js","/_next/static/immutable/chunks/3dc-1n866s65i.js","/_next/static/immutable/chunks/20x2y96ldu5wx.js","/_next/static/immutable/chunks/2w1bvggzb0ga8.js","/_next/static/immutable/chunks/2051ffx3xzio9.js"],"PaperListPageClient"] 30:T676,Atherosclerosis commences with endothelial dysfunction and the retention of cholesterol within the vessel wall, followed by a chronic inflammatory response. Lowering LDL-C (low-density lipoprotein-cholesterol; such as statins and PCSK9 [proprotein convertase subtilisin/kexin type 9] inhibitors) is the mainstay of current treatment for patients with atherosclerotic cardiovascular diseases, but residual inflammatory risk remains high. To address this pressing challenge, we used connectivity map screening of Food and Drug Administration-approved drugs, using perturbational data sets obtained from TNF-α (tumor necrosis factor-α) and IL (interleukin)-1β-stimulated human endothelial cells. Male and female This screening endeavor allows us to identify neratinib, a clinical drug against breast cancer, as the hit compound with broad anti-inflammatory actions in endothelial cells. Further studies reveal that neratinib inhibited endothelial cell inflammation elicited by 3 different proinflammatory stimuli (TNF-α, IL-1β, and lipopolysaccharide). Intriguingly, the anti-inflammatory effect of neratinib was independent of its classical target HER2 (human epidermal growth factor receptor 2)/ERBB2 inhibition. Further mechanistic investigation revealed that neratinib directly binds to ASK1 (apoptosis signal-regulating kinase 1) and suppresses ASK1 activation. Importantly, in both male and female Taken together, these findings support the concept that neratinib could be tested as a repurposed drug for vascular inflammation and atherosclerosis, thereby streamlining efforts to translate preclinical discoveries to clinical testing in humans.31:Td14, BACKGROUND: Atherosclerosis commences with endothelial dysfunction and the retention of cholesterol within the vessel wall, followed by a chronic inflammatory response. Lowering LDL-C (low-density lipoprotein-cholesterol; such as statins and PCSK9 [proprotein convertase subtilisin/kexin type 9] inhibitors) is the mainstay of current treatment for patients with atherosclerotic cardiovascular diseases, but residual inflammatory risk remains high. METHODS: To address this pressing challenge, we used connectivity map screening of Food and Drug Administration–approved drugs, using perturbational data sets obtained from TNF-α (tumor necrosis factor-α) and IL (interleukin)-1β–stimulated human endothelial cells. Male and female Ldlr −/− mouse models were used to evaluate the in vivo antiatherosclerotic effect of the hit compound identified. RESULTS: This screening endeavor allows us to identify neratinib, a clinical drug against breast cancer, as the hit compound with broad anti-inflammatory actions in endothelial cells. Further studies reveal that neratinib inhibited endothelial cell inflammation elicited by 3 different proinflammatory stimuli (TNF-α, IL-1β, and lipopolysaccharide). Intriguingly, the anti-inflammatory effect of neratinib was independent of its classical target HER2 (human epidermal growth factor receptor 2)/ERBB2 inhibition. Further mechanistic investigation revealed that neratinib directly binds to ASK1 (apoptosis signal-regulating kinase 1) and suppresses ASK1 activation. Importantly, in both male and female Ldlr −/− mice, treatment with neratinib decreased the plaque burden, reduced the necrotic core size, and mitigated lesional macrophage infiltration. Of translational impact, we observed that neratinib, in conjunction with the use of rosuvastatin (a standard lipid-lowering drug), produced superior antiatherosclerotic effects compared with statin monotherapy. Olink proteomics study pinpointed that combination treatment alleviated inflammation-related cytokines/chemokines in the serum from Ldlr −/− mice. CONCLUSIONS: Taken together, these findings support the concept that neratinib could be tested as a repurposed drug for vascular inflammation and atherosclerosis, thereby streamlining efforts to translate preclinical discoveries to clinical testing in humans. 25:[[["$","script","0",{"type":"application/ld+json","dangerouslySetInnerHTML":{"__html":"{\"@context\":\"https://schema.org\",\"@type\":\"CollectionPage\",\"name\":\"neratinib: generic Research & Clinical Takeaways\",\"description\":\"Explore peer-reviewed papers on neratinib (generic). Clinician-written summaries and actionable practice insights. Updated daily.\",\"url\":\"https://www.reachrx.ai/hub/tag/generic/neratinib\",\"breadcrumb\":{\"@type\":\"BreadcrumbList\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https://www.reachrx.ai\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Research Hub\",\"item\":\"https://www.reachrx.ai/hub\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Generics\",\"item\":\"https://www.reachrx.ai/hub/tag/generic\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"neratinib\",\"item\":\"https://www.reachrx.ai/hub/tag/generic/neratinib\"}]}}"}}]],["$","$L2f",null,{"title":"neratinib: Research & Clinical Takeaways","description":"Explore research on neratinib (generic) — efficacy, safety, and comparative data.","papers":[{"doi":"10.1016/j.jhep.2026.02.030","pmid":null,"title":"Systemic therapy of biliary tract cancer: The road to personalised strategies","journal_title":"Journal of Hepatology","journal_issn":"0168-8278","published_at":"2026-07-02T00:00:00.000Z","url":"https://doi.org/10.1016/j.jhep.2026.02.030","source_score":11,"is_retracted":false,"is_open_access":false,"raw_metadata":{"pubmed":false,"crossref":true,"unpaywall":true},"created_at":"2026-07-07T13:26:09.823Z","updated_at":"2026-07-07T13:26:09.823Z","tags":[{"paper_doi":"10.1016/j.jhep.2026.02.030","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1016/j.jhep.2026.02.030","tag_type":"brand","value":"Enhertu","value_numeric":null},{"paper_doi":"10.1016/j.jhep.2026.02.030","tag_type":"brand","value":"Lytgobi","value_numeric":null},{"paper_doi":"10.1016/j.jhep.2026.02.030","tag_type":"brand","value":"Pemazyre","value_numeric":null},{"paper_doi":"10.1016/j.jhep.2026.02.030","tag_type":"brand","value":"Tibsovo","value_numeric":null},{"paper_doi":"10.1016/j.jhep.2026.02.030","tag_type":"category","value":"Gastroenterology & Hepatology","value_numeric":null},{"paper_doi":"10.1016/j.jhep.2026.02.030","tag_type":"condition","value":"Ampullary Cancer","value_numeric":null},{"paper_doi":"10.1016/j.jhep.2026.02.030","tag_type":"condition","value":"Biliary Tract Cancer","value_numeric":null},{"paper_doi":"10.1016/j.jhep.2026.02.030","tag_type":"condition","value":"Cholangiocarcinoma","value_numeric":null},{"paper_doi":"10.1016/j.jhep.2026.02.030","tag_type":"condition","value":"Gallbladder Cancer","value_numeric":null},{"paper_doi":"10.1016/j.jhep.2026.02.030","tag_type":"generic","value":"dabrafenib","value_numeric":null},{"paper_doi":"10.1016/j.jhep.2026.02.030","tag_type":"generic","value":"durvalumab","value_numeric":null},{"paper_doi":"10.1016/j.jhep.2026.02.030","tag_type":"generic","value":"entrectinib","value_numeric":null},{"paper_doi":"10.1016/j.jhep.2026.02.030","tag_type":"generic","value":"futibatinib","value_numeric":null},{"paper_doi":"10.1016/j.jhep.2026.02.030","tag_type":"generic","value":"ivosidenib","value_numeric":null},{"paper_doi":"10.1016/j.jhep.2026.02.030","tag_type":"generic","value":"larotrectinib","value_numeric":null},{"paper_doi":"10.1016/j.jhep.2026.02.030","tag_type":"generic","value":"lirafugratinib","value_numeric":null},{"paper_doi":"10.1016/j.jhep.2026.02.030","tag_type":"generic","value":"neratinib","value_numeric":null},{"paper_doi":"10.1016/j.jhep.2026.02.030","tag_type":"generic","value":"pembrolizumab","value_numeric":null},{"paper_doi":"10.1016/j.jhep.2026.02.030","tag_type":"generic","value":"pemigatinib","value_numeric":null},{"paper_doi":"10.1016/j.jhep.2026.02.030","tag_type":"generic","value":"selpercatinib","value_numeric":null},{"paper_doi":"10.1016/j.jhep.2026.02.030","tag_type":"generic","value":"tinengotinib","value_numeric":null},{"paper_doi":"10.1016/j.jhep.2026.02.030","tag_type":"generic","value":"trametinib","value_numeric":null},{"paper_doi":"10.1016/j.jhep.2026.02.030","tag_type":"generic","value":"trastuzumab deruxtecan","value_numeric":null},{"paper_doi":"10.1016/j.jhep.2026.02.030","tag_type":"generic","value":"tucatinib","value_numeric":null},{"paper_doi":"10.1016/j.jhep.2026.02.030","tag_type":"generic","value":"zanidatamab","value_numeric":null},{"paper_doi":"10.1016/j.jhep.2026.02.030","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1016/j.jhep.2026.02.030","tag_type":"level_of_evidence","value":"5","value_numeric":null},{"paper_doi":"10.1016/j.jhep.2026.02.030","tag_type":"modality","value":"Antibody-Drug Conjugate","value_numeric":null},{"paper_doi":"10.1016/j.jhep.2026.02.030","tag_type":"modality","value":"BRAF/MEK Inhibitor","value_numeric":null},{"paper_doi":"10.1016/j.jhep.2026.02.030","tag_type":"modality","value":"FGFR Inhibitor","value_numeric":null},{"paper_doi":"10.1016/j.jhep.2026.02.030","tag_type":"modality","value":"HER2-Targeted Therapy","value_numeric":null},{"paper_doi":"10.1016/j.jhep.2026.02.030","tag_type":"modality","value":"IDH1 Inhibitor","value_numeric":null},{"paper_doi":"10.1016/j.jhep.2026.02.030","tag_type":"modality","value":"Immune Checkpoint Inhibitor","value_numeric":null},{"paper_doi":"10.1016/j.jhep.2026.02.030","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1016/j.jhep.2026.02.030","tag_type":"study_design","value":"Narrative Review","value_numeric":null},{"paper_doi":"10.1016/j.jhep.2026.02.030","tag_type":"warning","value":"HER2 IHC scoring in BTC is extrapolated from breast/gastric cancer criteria — no BTC-specific validated system exists, which may affect patient selection in practice.","value_numeric":null},{"paper_doi":"10.1016/j.jhep.2026.02.030","tag_type":"warning","value":"Several referenced trials (FIGHT-302, FOENIX-CCA3) were terminated early due to low accrual; results for some are still pending as of publication date.","value_numeric":null},{"paper_doi":"10.1016/j.jhep.2026.02.030","tag_type":"warning","value":"Some emerging targets (MTAP, MDM2, MET, RAS) are represented only by early-phase or case-series data; these should not be considered standard of care.","value_numeric":null},{"paper_doi":"10.1016/j.jhep.2026.02.030","tag_type":"warning","value":"The paper's DOI suggests a 2026 publication date, which is consistent with today's date; some cited references are also from 2025–2026 and may not yet be widely available.","value_numeric":null},{"paper_doi":"10.1016/j.jhep.2026.02.030","tag_type":"warning","value":"This is a narrative review (not a systematic review or meta-analysis); clinical outcome data cited are from individual trials with varying designs and patient populations.","value_numeric":null}],"summaries":{"what_studied":"This review covers the evolving systemic therapy landscape of biliary tract cancer (BTC), including cholangiocarcinoma, gallbladder cancer, and ampullary cancer, with a focus on chemo-immunotherapy as first-line standard of care and precision oncology strategies targeting FGFR2 fusions, IDH1 mutations, HER2 alterations, and tumour-agnostic biomarkers (BRAF V600E, MSI-H/dMMR, RET/NTRK/NRG1 fusions).","key_result":"Chemo-immunotherapy (CisGem + durvalumab or pembrolizumab) is now first-line standard of care; approved targeted agents include pemigatinib (ORR 37%, mPFS 7.0 mo, mOS 17.5 mo) and futibatinib (ORR 42%, mPFS 9.0 mo, mOS 21.7 mo) for FGFR2 fusion+ iCCA, ivosidenib for IDH1-mutant CCA (mOS 10.3 mo vs. 7.5 mo placebo, crossover-adjusted HR 0.49), and zanidatamab for HER2 IHC3+ BTC (ORR 41.3%, mOS 15.5 mo); lirafugratinib shows promising next-gen FGFR2 selectivity (ORR 47%, mPFS 11.3 mo, mOS 22.8 mo).","limitations":"- All targeted therapy approvals are in previously treated patients only; no first-line phase III targeted therapy trial has completed successfully (three closed early due to low accrual).\n- Biomarker testing is heterogeneous and incompletely standardised, with up to 25% of tissue samples failing NGS; no BTC-specific HER2 IHC scoring system exists.\n- This is a narrative review without systematic methods or meta-analysis; cross-trial comparisons are confounded by differing patient populations and the potential prognostic effect of molecular subtypes.","practice_takeaway":"All patients with advanced BTC should receive hybrid-capture DNA/RNA NGS at diagnosis to identify actionable alterations (FGFR2 fusions, IDH1 mutations, HER2 status, and tumour-agnostic targets) before second-line therapy decisions are made. In the absence of a targetable alteration, CisGem plus durvalumab or pembrolizumab is first-line standard of care; when actionable alterations are found, approved targeted agents should be prioritised over second-line chemotherapy."}},{"doi":"10.1161/circresaha.125.326508","pmid":"41510568","title":"Neratinib, a Clinical Drug Against Breast Cancer, Protects Against Vascular Inflammation and Atherosclerosis","journal_title":"Circulation Research","journal_issn":"0009-7330","published_at":"2026-01-09T00:00:00.000Z","url":"https://doi.org/10.1161/circresaha.125.326508","source_score":14,"is_retracted":false,"is_open_access":false,"raw_metadata":{"ooir":{"day":"2026-01-11","doi":"10.1161/circresaha.125.326508","days":"7","issn":"0009-7330","rank":"9","field":"Clinical Medicine","score":"14","category":"Hematology","categories":["Hematology"],"_categories":["Hematology"]},"pubmed":{"doi":"10.1161/CIRCRESAHA.125.326508","title":"Neratinib, a Clinical Drug Against Breast Cancer, Protects Against Vascular Inflammation and Atherosclerosis.","journal":"Circulation research","methods":"","results":"This screening endeavor allows us to identify neratinib, a clinical drug against breast cancer, as the hit compound with broad anti-inflammatory actions in endothelial cells. Further studies reveal that neratinib inhibited endothelial cell inflammation elicited by 3 different proinflammatory stimuli (TNF-α, IL-1β, and lipopolysaccharide). Intriguingly, the anti-inflammatory effect of neratinib was independent of its classical target HER2 (human epidermal growth factor receptor 2)/ERBB2 inhibition. Further mechanistic investigation revealed that neratinib directly binds to ASK1 (apoptosis signal-regulating kinase 1) and suppresses ASK1 activation. Importantly, in both male and female ","abstract":"$30","keywords":["MAP kinase kinase kinase 5","atherosclerosis","cardiovascular diseases","endothelial cells","foam cells"],"pubmed_id":"41510568","conclusions":"","publication_date":"2026-01-09T00:00:00"},"crossref":{"DOI":"10.1161/circresaha.125.326508","URL":"https://doi.org/10.1161/circresaha.125.326508","ISSN":["0009-7330","1524-4571"],"link":[{"URL":"https://www.ahajournals.org/doi/full/10.1161/CIRCRESAHA.125.326508","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"page":null,"type":"journal-article","issue":null,"score":1,"title":["Neratinib, a Clinical Drug Against Breast Cancer, Protects Against Vascular Inflammation and Atherosclerosis"],"author":[{"given":"Fan-Shun","family":"Zhang","sequence":"first","affiliation":[{"name":"Division of Life Sciences and Medicine, Department of Endocrinology and Metabolism, Centre for Leading Medicine and Advanced Technologies of IHM, The First Affiliated Hospital of University of Science and Technology of China (USTC), USTC, Hefei. (F.-S.Z., C.H., Z.W., J.W., S.X.)"},{"name":"Department of Cardiology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China (F.-S.Z., J.-Y.L.)."}]},{"given":"Chenyang","family":"He","sequence":"additional","affiliation":[{"name":"Division of Life Sciences and Medicine, Department of Endocrinology and Metabolism, Centre for Leading Medicine and Advanced Technologies of IHM, The First Affiliated Hospital of University of Science and Technology of China (USTC), USTC, Hefei. (F.-S.Z., C.H., Z.W., J.W., S.X.)"}]},{"given":"Yanjun","family":"Yin","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Bengbu Medical University, China (Y.Y.)."}]},{"given":"Zhihua","family":"Wang","sequence":"additional","affiliation":[{"name":"Division of Life Sciences and Medicine, Department of Endocrinology and Metabolism, Centre for Leading Medicine and Advanced Technologies of IHM, The First Affiliated Hospital of University of Science and Technology of China (USTC), USTC, Hefei. (F.-S.Z., C.H., Z.W., J.W., S.X.)"}]},{"given":"Xiumei","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Guangdong Geriatrics Institute, Guangdong Provincial People’s Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, China (X.W.)."}]},{"given":"Danielle","family":"Kamato","sequence":"additional","affiliation":[{"name":"Institute for Biomedicine and Glycomics, Griffith University, Nathan, QLD, Australia (D.K.)."}]},{"given":"Ruixue","family":"Leng","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, Hefei, China (R.L.)."}]},{"given":"Jiang-Yun","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Cardiology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China (F.-S.Z., J.-Y.L.)."}]},{"given":"Jianping","family":"Weng","sequence":"additional","affiliation":[{"name":"Division of Life Sciences and Medicine, Department of Endocrinology and Metabolism, Centre for Leading Medicine and Advanced Technologies of IHM, The First Affiliated Hospital of University of Science and Technology of China (USTC), USTC, Hefei. (F.-S.Z., C.H., Z.W., J.W., S.X.)"},{"name":"Institute of Endocrine and Metabolic Diseases, USTC, Hefei. (J.W., S.X.)"},{"name":"Anhui Provincial Key Laboratory of Metabolic Health and Panvascular Diseases, Hefei, China (J.W., S.X.)."}]},{"given":"Suowen","family":"Xu","sequence":"additional","affiliation":[{"name":"Division of Life Sciences and Medicine, Department of Endocrinology and Metabolism, Centre for Leading Medicine and Advanced Technologies of IHM, The First Affiliated Hospital of University of Science and Technology of China (USTC), USTC, Hefei. (F.-S.Z., C.H., Z.W., J.W., S.X.)"},{"name":"Institute of Endocrine and Metabolic Diseases, USTC, Hefei. (J.W., S.X.)"},{"name":"Anhui Provincial Key Laboratory of Metabolic Health and Panvascular Diseases, Hefei, China (J.W., S.X.)."}]}],"issued":{"date-parts":[[2026,1,9]]},"member":"276","prefix":"10.1161","source":"Crossref","volume":null,"created":{"date-time":"2026-01-09T10:00:12Z","timestamp":1767952812000,"date-parts":[[2026,1,9]]},"indexed":{"date-time":"2026-01-09T11:42:43Z","timestamp":1767958963884,"date-parts":[[2026,1,9]]},"subject":[],"abstract":"$31","language":"en","relation":{},"resource":{"primary":{"URL":"https://www.ahajournals.org/doi/10.1161/CIRCRESAHA.125.326508"}},"subtitle":[],"assertion":[{"name":"received","group":{"name":"publication_history","label":"Publication History"},"label":"Received","order":0,"value":"2025-03-14"},{"name":"revised","group":{"name":"publication_history","label":"Publication History"},"label":"Revised","order":1,"value":"2025-11-25"},{"name":"accepted","group":{"name":"publication_history","label":"Publication History"},"label":"Accepted","order":2,"value":"2025-12-05"},{"name":"published","group":{"name":"publication_history","label":"Publication History"},"label":"Published","order":3,"value":"2026-01-09"}],"deposited":{"date-time":"2026-01-09T10:00:13Z","timestamp":1767952813000,"date-parts":[[2026,1,9]]},"issn-type":[{"type":"print","value":"0009-7330"},{"type":"electronic","value":"1524-4571"}],"published":{"date-parts":[[2026,1,9]]},"publisher":"Ovid Technologies (Wolters Kluwer Health)","reference":[{"DOI":"10.1124/pharmrev.120.000096","key":"e_1_3_3_2_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1124/pr.118.017178","key":"e_1_3_3_3_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1038/s41586-021-03392-8","key":"e_1_3_3_4_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.vph.2023.107255","key":"e_1_3_3_5_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1161/CIR.0000000000001309","key":"e_1_3_3_6_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.atherosclerosis.2019.12.004","key":"e_1_3_3_7_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.plipres.2019.101006","key":"e_1_3_3_8_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.3389/fimmu.2022.976722","key":"e_1_3_3_9_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.3389/fcvm.2022.925923","key":"e_1_3_3_10_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/S0140-6736(24)00968-1","key":"e_1_3_3_11_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1038/s41401-021-00835-w","key":"e_1_3_3_12_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1056/NEJMoa1707914","key":"e_1_3_3_13_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/S0140-6736(17)32814-3","key":"e_1_3_3_14_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/S0140-6736(21)00520-1","key":"e_1_3_3_15_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1038/nrd.2018.168","key":"e_1_3_3_16_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.cmet.2023.06.011","key":"e_1_3_3_17_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.cell.2017.10.049","key":"e_1_3_3_18_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1126/science.1132939","key":"e_1_3_3_19_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.ygyno.2015.08.002","key":"e_1_3_3_20_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.4103/0976-0105.177703","key":"e_1_3_3_21_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.imbio.2023.152753","key":"e_1_3_3_22_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.3389/fcvm.2018.00055","key":"e_1_3_3_23_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.3389/fphar.2022.1040999","key":"e_1_3_3_24_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1038/s41598-017-06202-2","key":"e_1_3_3_25_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1126/sciadv.aau0731","key":"e_1_3_3_26_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaccao.2022.06.004","key":"e_1_3_3_27_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1183/13993003.01110-2015","key":"e_1_3_3_28_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1182/blood-2018-10-881557","key":"e_1_3_3_29_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1093/annonc/mdw282","key":"e_1_3_3_30_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.7150/ijbs.39414","key":"e_1_3_3_31_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1161/CIRCULATIONAHA.105.540542","key":"e_1_3_3_32_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":null,"key":"e_1_3_3_33_2","year":"2021","issue":null,"author":"Filik Y","volume":"11","first-page":"6042","unstructured":"Filik Y, Bauer K, Hadzijusufovic E, Haider P, Greiner G, Witzeneder N, Hoermann G, Hohensinner PJ, Gleixner KV, Wojta J, et al. PI3-kinase inhibition as a strategy to suppress the leukemic stem cell niche in Ph plus chronic myeloid leukemia. Am J Cancer Res. 2021;11:6042–6059.","article-title":"PI3-kinase inhibition as a strategy to suppress the leukemic stem cell niche in Ph plus chronic myeloid leukemia.","journal-title":"Am J Cancer Res","doi-asserted-by":null},{"DOI":"10.3389/fcvm.2018.00125","key":"e_1_3_3_34_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.vph.2021.106949","key":"e_1_3_3_35_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.bcp.2022.115155","key":"e_1_3_3_36_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.7150/ijbs.74864","key":"e_1_3_3_37_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/bph.12991","key":"e_1_3_3_38_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1172/JCI11871","key":"e_1_3_3_39_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1093/cvr/cvad130","key":"e_1_3_3_40_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1038/s41591-023-02461-x","key":"e_1_3_3_41_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1136/bmj-2023-076065","key":"e_1_3_3_42_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1200/JCO.20.00147","key":"e_1_3_3_43_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1158/1078-0432.CCR-21-3177","key":"e_1_3_3_44_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1126/science.275.5296.90","key":"e_1_3_3_45_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1001/jamainternmed.2021.5714","key":"e_1_3_3_46_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1056/NEJMra1515161","key":"e_1_3_3_47_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/S0140-6736(23)00215-5","key":"e_1_3_3_48_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.tips.2024.04.009","key":"e_1_3_3_49_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.3390/molecules27030819","key":"e_1_3_3_50_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/cns.13735","key":"e_1_3_3_51_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1038/ncb3149","key":"e_1_3_3_52_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1073/pnas.122249299","key":"e_1_3_3_53_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1038/nrcardio.2015.65","key":"e_1_3_3_54_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1161/CIRCULATIONAHA.123.067005","key":"e_1_3_3_55_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.yjmcc.2020.11.009","key":"e_1_3_3_56_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1096/fj.201801690R","key":"e_1_3_3_57_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.cardfail.2016.01.013","key":"e_1_3_3_58_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1007/s40265-017-0811-4","key":"e_1_3_3_59_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.annonc.2023.08.003","key":"e_1_3_3_60_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1182/blood.v128.22.3719.3719","key":"e_1_3_3_61_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1038/cdd.2011.93","key":"e_1_3_3_62_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1126/science.1101909","key":"e_1_3_3_63_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1161/ATVBAHA.111.227140","key":"e_1_3_3_64_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1161/atvbaha.121.316662","key":"e_1_3_3_65_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1093/cvr/cvs295","key":"e_1_3_3_66_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.ajpath.2012.10.008","key":"e_1_3_3_67_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1161/01.CIR.0000096486.01652.FC","key":"e_1_3_3_68_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.2147/Dddt.S231916","key":"e_1_3_3_69_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1161/hc0402.102863","key":"e_1_3_3_70_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1158/1538-7445.Am2024-4828","key":"e_1_3_3_71_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1093/eurheartj/ehaf260","key":"e_1_3_3_72_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.33678/cor.2023.032","key":"e_1_3_3_73_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1093/annonc/mdy533","key":"e_1_3_3_74_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1056/NEJMoa1703643","key":"e_1_3_3_75_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/S1470-2045(13)70335-8","key":"e_1_3_3_76_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.clbc.2023.10.007","key":"e_1_3_3_77_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1038/s44161-024-00591-0","key":"e_1_3_3_78_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1093/cvr/cvy132","key":"e_1_3_3_79_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1007/978-1-4939-2929-0_6","key":"e_1_3_3_80_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1161/ATVBAHA.124.322252","key":"e_1_3_3_81_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1038/s41401-024-01317-5","key":"e_1_3_3_82_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1093/bioinformatics/bty560","key":"e_1_3_3_83_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1186/s12916-022-02436-8","key":"e_1_3_3_84_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.apsb.2020.01.017","key":"e_1_3_3_85_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1126/science.1233606","key":"e_1_3_3_86_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1021/acs.jnatprod.6b00627","key":"e_1_3_3_87_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.celrep.2020.108491","key":"e_1_3_3_88_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1038/s42003-022-04056-7","key":"e_1_3_3_89_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1161/ATVBAHA.120.315373","key":"e_1_3_3_90_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"}],"short-title":[],"update-policy":"https://doi.org/10.1161/crossmarkpolicy","alternative-id":["10.1161/CIRCRESAHA.125.326508"],"article-number":"CIRCRESAHA.125.326508","content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"original-title":[],"container-title":["Circulation Research"],"reference-count":89,"published-online":{"date-time":null,"timestamp":null,"date-parts":[[2026,1,9]]},"references-count":89,"short-container-title":["Circulation Research"],"is-referenced-by-count":0},"unpaywall":{"doi":"10.1161/circresaha.125.326508","is_oa":false,"title":"Neratinib, a Clinical Drug Against Breast Cancer, Protects Against Vascular Inflammation and Atherosclerosis","updated":"2026-01-10T04:46:20+00:00","published_date":"2026-01-09","best_oa_location":null}},"created_at":"2026-01-14T18:30:49.575Z","updated_at":"2026-01-17T09:03:27.421Z","tags":[{"paper_doi":"10.1161/circresaha.125.326508","tag_type":"brand","value":"Nerlynx","value_numeric":null},{"paper_doi":"10.1161/circresaha.125.326508","tag_type":"category","value":"Hematology","value_numeric":null},{"paper_doi":"10.1161/circresaha.125.326508","tag_type":"condition","value":"Atherosclerosis","value_numeric":null},{"paper_doi":"10.1161/circresaha.125.326508","tag_type":"generic","value":"neratinib","value_numeric":null},{"paper_doi":"10.1161/circresaha.125.326508","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.1161/circresaha.125.326508","tag_type":"modality","value":"Tyrosine Kinase Inhibitor","value_numeric":null},{"paper_doi":"10.1161/circresaha.125.326508","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1161/circresaha.125.326508","tag_type":"study_design","value":"Preclinical Study","value_numeric":null},{"paper_doi":"10.1161/circresaha.125.326508","tag_type":"warning","value":"Study is preclinical; standard clinical study design labels may not apply.","value_numeric":null},{"paper_doi":"10.1161/circresaha.125.326508","tag_type":"warning","value":"The abstract text appears truncated; animal model details, sample sizes, and quantitative outcomes are not available.","value_numeric":null}],"summaries":{"what_studied":"Connectivity map screening of FDA-approved drugs using perturbational gene signatures from TNF-α– and IL-1β–stimulated human endothelial cells to identify anti-inflammatory candidates, with follow-up mechanistic testing of neratinib.","key_result":"Neratinib reduced endothelial inflammatory responses to TNF-α, IL-1β, and LPS; this effect was independent of HER2/ERBB2 and involved direct binding to ASK1 with inhibition of ASK1 activation.","limitations":"Evidence presented is preclinical and centered on endothelial cell assays; in vivo details, sample sizes, and quantitative outcomes are not provided in the text excerpt."}}],"initialOffset":2,"fetchConfig":{"kind":"tags","tags":[{"tag_type":"generic","value":"neratinib"}]},"breadcrumbItems":[{"name":"Home","href":"/"},{"name":"Research Hub","href":"/hub"},{"name":"Generics","href":"/hub/tag/generic"},{"name":"neratinib"}],"hrefConfig":{"basePath":"/hub/papers","webViewQueryParams":{"hub_ctx":"tag","hub_tag_type":"generic","hub_tag_value":"neratinib"}}}]]

Papers